Slide 1: HY16 Interim Results Presentation
HY16 Interim Results Presenta3on For the six months to 30 September 2015 26 November 2015 David Darling, CEO
Slide 2: HY16 Highlights
HY16 HIGHLIGHTS Con$nuing Growth in Increased Presence in Progressed Evalua$on Rollout of Second Commercial Revenue USA Market into South East Asia Product, Cxbladder Triage Progression of USA sales Expanded the sales Ini3ated User Launched in NZ in late strategy and increasing team to 16 specialist
Slide 3: HY16 Revenue
HY16 REVENUE 2 PRODUCT SALES Con3nuing growth in product sales, par3cularly in North America 1.5 238% increase in product sales 1 compared to the Commercial revenue has more than tripled since the NZ$Million same six months previous first half year, and is almost equal to full 0.5 last year year sale
Slide 4: HY16 Investment
HY16 INVESTMENT CONTINUING INVESTMENT IN FOUR STRATEGIC AREAS • Expansion of the USA sales team PEOPLE • Increased the commercial and product development teams in New Zealand • Commenced launch of Cxbladder Triage into the USA PRODUCT DEVELOPMENT • Development of Cxbladder Monitor for launch in New
Slide 5: Funding for Growth
FUNDING FOR GROWTH Cash and cash equivalents $32.72 million as at 30 September 2015 Debt free with funding from capital and technology grants for new product development, commercialisa3on, USA rollout and inves3ga3on into South East Asia Successful capital raising with a total of $35.3 million raise
Slide 6: Progress Against FY16 Objectives: USA Healthcare Market
PROGRESS AGAINST FY16 OBJECTIVES USA HEALTHCARE MARKET FY16 OBJECTIVE HY16 PROGRESS TO DATE Build Infrastructure for Growth Recruited four out of a planned six sales people, growing the sales team to 16 specialists targe3ng 19 sales regions. Expand to 18 sales execu3ves covering 19 targeted major me
Slide 7: Progress Against FY16 Objectives: User Programmes
PROGRESS AGAINST FY16 OBJECTIVES USER PROGRAMMES FY16 OBJECTIVE HY16 PROGRESS TO DATE Enhance Awareness and Foster Strong User Programmes: These are a key component of the adop3on of Cxbladder tests by urologists Adop$on Con3nued to build the number of User Programmes with a focus on Large Urology G
Slide 8: Progress Against FY16 Objectives: USA Healthcare Market
PROGRESS AGAINST FY16 OBJECTIVES USA HEALTHCARE MARKET FY16 OBJECTIVE HY16 PROGRESS TO DATE Capture Transforma$onal Customers Veterans Administra$on (VA) Complete the Veterans Administra3on Con3nuing to progress discussions to gain registra3on on the Federal (VA) and Centre for Medicaid and Supply S
Slide 9: Progress Against FY16 Objectives: South East Asia
PROGRESS AGAINST FY16 OBJECTIVES SOUTH EAST ASIA FY16 OBJECTIVE HY16 PROGRESS TO DATE Grow Our Interna$onal Presence Entered into a User Programme Study with a leading hospital in Singapore earlier in the half year to generate data specific to Finalise business case for entry into the Singapore and t
Slide 10: Progress Against FY16 Objectives: Product Development
PROGRESS AGAINST FY16 OBJECTIVES PRODUCT DEVELOPMENT FY16 OBJECTIVE Deliver a ‘One Stop Shop’ To be used by clinicians and physicians responsible for the primary of Cxbladder Products Cxbladder Triage detec3on of bladder cancer as a frontline tool in the early evalua3on of In-‐Market 2014/15 haemat
Slide 11: Deliver a 'One Stop Shop' of Cxbladder Products
PROGRESS AGAINST FY16 OBJECTIVES DELIVER A ‘ONE STOP SHOP’ OF CXBLADDER PRODUCTS FY16 OBJECTIVE HY16 PROGRESS TO DATE Launch Cxbladder Triage in the USA Con3nuing to roll out Cxbladder Triage in New Zealand following launch in December 2014 Bring into commercialisa3on Cxbladder Commenced launch into
Slide 12: Engage with the People Who Matter
PROGRESS AGAINST FY16 OBJECTIVES ENGAGE WITH THE PEOPLE WHO MATTER FY16 OBJECTIVE HY16 PROGRESS TO DATE Launch online pa$ent community for Pacific Edge is the leading sponsor of bladdercancer.me, developed and bladder cancer pa$ents, bladdercancer.me empowered by Melon Health Provides online, relevan
Slide 13: Looking Forward
LOOKING FORWARD PRIORITIES FOR 2H16 MARKETS SALES CHANNELS • Expand our sales presence in the USA • Iden3fy new opportuni3es to market and sell our products • Con3nue to test opportunity in South East Asia, con3nue to • Finalise the process with the Veterans Administra3on and Centre for support curr
Slide 14: Strategic Opportunities for Growth
STRATEGIC OPPORTUNITIES FOR GROWTH Targe3ng High Growth Over The Medium Term by Crea3ng More Products and Building Sales in an Increasing Number of Markets • Development of suite of Cxbladder products More Products • IP over other cancer expressions with opportunity to develop specific diagnos3c test
Slide 15: Question and Answer
QUESTION AND ANSWER Pacific Edge 2016 Interim Results Presenta3on 15
Slide 16: www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com
www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com David Darling Chief Execu3ve Officer Pacific Edge Limited Tel: +64 3 479 5802 Mobile: +64 21 797981 Email: dave.darling@pelnz.com Pacific Edge 2016 Interim Results Presenta3on
Slide 17: Disclaimer
DISCLAIMER Informa$on The informa3on in this presenta3on is an overview and does not contain all informa3on necessary to make an investment decision. It is intended to cons3tute a summary of certain informa3on rela3ng to the performance of Pacific Edge Limited . The informa3on in this presenta3on is